



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: June 30, 2006

To: NCCTG Primary Clinical Research Associates

From: Lori Bratvold
Protocol Development Coordinator

Re: N0177, A Phase I/II Study of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Due to Study 3 permanently closing, the eligibility checklist has been revised to delete reference to Study 3. Please replace your current version of this checklist with the attached revised version.

If you have any questions concerning this communication, please contact me at 507/266-3549.

Thank you.

LB/dg
enclosure